Inma Hernandez Talks Drug Pricing on WESA

January 14, 2019

“Pharmaceutical manufacturers realize our health care system is very fragmented, and payers don’t have, in many cases, much leverage,” CP3 Associate Director Inma Hernandez told WESA-FM's Sarah Boden. “So, they take advantage of that.” Hernandez spoke with Boden about a drug pricing study she led. The study determined that the prices of brand name drugs are increasing faster than inflation.